View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
Large prospective studies are needed.
Aspirin has long been used in the prevention of recurrent disease in people with symptomatic coronary artery disease and cerebrovascular disease and has been recommended in those with peripheral artery disease (PAD). But evidence to support its use in people with PAD hasn't been established. In a metaanalysis to investigate this, the authors identified 18 trials (N = 5,269) of patients with PAD who were randomized to aspirin treatment or placebo or a control group, and which included data on mortality, myocardial infarction, stroke, and major bleeding.
The results show that aspirin therapy alone or in combination with dipyridamole did not significantly reduce cardiovascular events in patients with PAD, however it did reduce the risk of nonfatal stroke. The authors suggest that these findings could be related to an underrepresentation of patients with PAD in clinical trials.
The crux of the matter. The metaanalysis found a small but not significant benefit of aspirin therapy in patients with coronary artery disease and an association between aspirin therapy and a significant reduction in nonfatal stroke in patients with PAD. Until large prospective studies are undertaken, the benefits and risks of aspirin therapy can neither be confirmed nor denied in patients with PAD.
Berger JS, et al. JAMA 2009;301(18):1909-19.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top